1.Lyu Z, Feng X, Li N, Zhao W, Wei L, Chen Y, et al. Human papillomavirus in semen and the risk for male infertility: a systematic review and meta-analysis. BMC infectious diseases. 2017;17(1):714.
2.World Health Organization (WHO). Human papillomavirus (HPV) and cervical cancer: World Health Organization (WHO),; 2019 [updated 2019/01/24. Available from: https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer.
3.Braaten KP, Laufer MR. Human Papillomavirus (HPV), HPV-Related Disease, and the HPV Vaccine. Rev Obstet Gynecol. 2008;1(1):2–10.
4.Kraut AA, Schink T, Schulze-Rath R, Mikolajczyk RT, Garbe E. Incidence of anogenital warts in Germany: a population-based cohort study. BMC infectious diseases. 2010;10:360.
5.Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician. 2004;70(12):2335–42.
6.Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC infectious diseases. 2013;13:39-.
7.Thöne K, Horn J, Mikolajczyk R. Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data. BMC infectious diseases. 2017;17(1):564-.
8.Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244–65.
9.Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
10.Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland. Krebs in Deutschland für 2013/2014. Berlin: Robert Koch-Institut; 2017.
11.Hartwig S, Baldauf J-J, Dominiak-Felden G, Simondon F, Alemany L, de Sanjosé S, et al. Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines. Papillomavirus Research. 2015;1:90–100.
12.Reuschenbach M, Roos J, Panayotopoulos D, Baldus SE, Schnürch H-G, Berger A, et al. Characterization of Squamous Cell Cancers of the Vulvar Anterior Fourchette by Human Papillomavirus, p16INK4a, and p53. Journal of Lower Genital Tract Disease. 2013;17(3):289–97.
13.European Medicines Agency. HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS London, United Kingdom2016 [Available from: https://www.ema.europa.eu/en/documents/referral/hpv-vaccines-article–20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-pots_en.pdf.
14.Robert Koch-Institut. Impfquoten bei der Schuleingangsuntersuchung in Deutschland 2014. Epidemiologisches Bulletin,. 2016;16/2014:129–42.
15.Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23.
16.Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7(1):38.
17.Robert Koch-Institut. Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren—Empfehlung und Begründung. Epidemiologisches Bulletin. 2007;12/2007:97–106.
18.Takla A, Wiese-Posselt M, Harder T, Meerpohl JJ, Röbl-Mathieu M, Terhardt M, et al. Background paper for the recommendation of HPV vaccination for boys in Germany. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2018;61(9):1170–86.
19.Robert Koch-Institut. Wissenschaftliche Begründung für die Empfehlung der HPV-Impfung für Jungen im Alter von 9 bis 14 Jahren. Epidemiologisches Bulletin,. 2018;26/2018:233–54.
20.Hense S, Hillebrand K, Horn J, Mikolajczyk R, Schulze-Rath R, Garbe E. HPV vaccine uptake after introduction of the vaccine in Germany: an analysis of administrative data. Hum Vaccin Immunother. 2014;10(6):1729–33.
21.Robert Koch-Institut. Aktuelles aus der KV-Impfsurveillance—Impfquoten ausgewählter Schutzimpfungen in Deutschland. Epidemiologisches Bulletin. 2018;1/2018.
22.Robert Koch-Institut. Vaccination againsthuman papillomavirus (HPV) in girls. Fact sheet on KiGGS Wave 1: German Health Interview and Examination Survey for Children and Adolescents—First follow-up interview 2009−2012. 2014.
23.Geyer S, Jaunzeme J, Hillemanns P. Cervical cancer screening in Germany: group-specific participation rates in the state of Niedersachsen (Lower Saxony). A study with health insurance data. Archives of gynecology and obstetrics. 2015;291(3):623–9.
24.Andersohn F, Walker J. Characteristics and external validity of the German Health Risk Institute (HRI) Database. Pharmacoepidemiology and drug safety. 2016;25(1):106–9.
25.Agresti A, Coull BA. Approximate Is Better than “Exact” for Interval Estimation of Binomial Proportions. The American Statistician. 1998;52(2):119–26.
26.Delere Y, Remschmidt C, Leuschner J, Schuster M, Fesenfeld M, Schneider A, et al. Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC infectious diseases. 2014;14:87.
27.National HPV Vaccination Program Register. National (Australia) HPV 3 dose vaccination coverage for females turning 15 years of age in 2015 2018 [Available from: http://www.hpvregister.org.au/site/DefaultSite/filesystem/documents/Coverage-Data/2018/Coverage%20by%20dose%202015%20-%20females.pdf.
28.Mikolajczyk RT, Kraut AA, Horn J, Schulze-Rath R, Garbe E. Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study. Sexually transmitted diseases. 2013;40(1):28–31.
29.Petry KU, Luyten A, Justus A, Iftner A, Strehlke S, Schulze-Rath R, et al. Prevalence of low-risk HPV types and genital warts in women born 1988/89 or 1983/84 - results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC infectious diseases. 2012;12:367.
30.Petry KU, Luyten A, Justus A, Iftner A, Strehlke S, Reinecke-Luthge A, et al. Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84 - results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC infectious diseases. 2013;13:135.
31.Chow EPF, Read TRH, Wigan R, Donovan B, Chen MY, Bradshaw CS, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sexually Transmitted Infections. 2015;91(3):214–9.
32.Zentrum für Krebsregisterdaten (ZfKD). Datenbankabfrage 2017 [Available from: https://www.krebsdaten.de/Krebs/SiteGlobals/Forms/Datenbankabfrage/datenbankabfrage_stufe2_form.html.
33.Dittmer C, Katalinic A, Mundhenke C, Thill M, Fischer D. Epidemiology of vulvar and vaginal cancer in Germany. Archives of gynecology and obstetrics. 2011;284(1):169–74.
34.Garland SM, Kjaer SK, Munoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2016;63(4):519–27.
35.Mariani L, Vici P, Suligoi B, Checcucci-Lisi G, Drury R. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Advances in therapy. 2015;32(1):10–30.
36.Deutsches Institut für Medizinische Dokumentation und Information (DIMDI). ICD–10-GM - Versionsverlauf und Bekanntmachungen: Deutsches Institut für Medizinische Dokumentation und Information; 2019 [Available from: https://www.dimdi.de/dynamic/de/klassifikationen/icd/icd–10-gm/historie/versionsverlauf/.